Volume 28, Number 6—June 2022
CME ACTIVITY - Synopsis
Antimicrobial-Resistant Shigella spp. in San Diego, California, USA, 2017–2020
Table 2
Patient variable | Shigella flexneri, no. (%) | Shigella sonnei, no. (%) | p value |
---|---|---|---|
HIV positive | 44 (68) | 21 (43) | 0.008 |
Sexual orientation, GBM/transgender woman | 45 (85) | 26 (68) | 0.061 |
HAART use by persons living with HIV | 40 (91) | 15 (71) | 0.065 |
PrEP use among HIV-negative | 4 (80) | 4 (57) | 0.408 |
Unhoused | 6 (8) | 23 (40) | <0.001 |
Methamphetamine use | 16 (23) | 26 (46) | 0.006 |
Travel | 11 (15) | 9 (20) | 0.008 |
*GBM, gay and bisexual man; HAART, highly active antiretroviral therapy; PrEP, preexposure prophylaxis.
Page created: April 11, 2022
Page updated: May 23, 2022
Page reviewed: May 23, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.